Antibody is fixed on the Human tweak； Variant epitope Chimeric, Humanized or reduced T cells； Pharmaceutical composition comprising the Antibody； Antibody used to treat cancer, autoimmune diseases and other diseases； Nucleic Acid Expression Vectors and C Elula host containing the coding sequence of the Antibody before mentioned.
The invention provides antibodies binding to TWEAK, including anti-TWEAK antibodies comprising a heavy chain variable domain CDR3 (CDR3H) selected from the group consisting of SEQ ID NO: 8, 16 or 24. The invention provides anti-TWEAK antibodies which are useful for the treatment of cancer, autoimmune diseases, rheumatoid arthritis, psoratic arthritis, muscle diseases, e.g. muscular dystrophy, multiple sclerosis, chronic kidney diseases, bone diseases, e.g. bone degeneration in multiple myeloma, systemic lupus erythematosus, lupus nephritis, and vascular injury.ANTICUERPO QUE SE FIJA SOBRE LA TWEAK HUMANA； VARIANTE QUIMERICA, HUMANIZADA O REDUCIDA DEL EPITOPE DE LAS CELULAS T； COMPOSICION FARMACEUTICA QUE COMPRENDE EL ANTICUERPO； USO DEL ANTICUERPO PARA TRATAR CANCER, ENFERMEDADES AUTOINMUNES Y OTRAS ENFERMEDADES； ACIDO NUCLEICO, VECTORES DE EXPRESION Y CELULA HUESPED QUE COMPRENDEN LA SECUENCIA CODIFICANTE DEL ANTICUERPO ANTES MENCIONADO.
